• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

    1.200 -0.030 (-2.44%)
    Streaming Delayed Price Updated: 10:32 AM EST, Feb 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Estrella Immunopharma, Inc. - Common Stock

    < Previous 1 2 Next >
    Monday's pre-market session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
    From Estrella Immunopharma, Inc.
    Via Business Wire
    Curious about the stocks that are showing activity after the closing bell on Friday? ↗
    Via Chartmill
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
    From Estrella Immunopharma, Inc.
    Via Business Wire
    BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
    Via Investor Brand Network
    News headline image
    Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Tuesday's session: top gainers and losers ↗
    Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Which stocks are moving on Monday? ↗
    Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
    Via Chartmill
    News headline image
    Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week ↗
    Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments. 
    Via Stocktwits
    News headline image
    Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
    From Estrella Immunopharma
    Via Business Wire
    News headline image
    Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
    From Estrella Immunopharma, Inc.
    Via Business Wire
    News headline image
    This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.